DAY301 | Day One Biopharmaceuticals

Cancer research · Adenoid cystic carcinoma

Emi‑Le is an investigational product that has demonstrated early anti‑tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma (ACC).

Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.

Original source

Related signals

• Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features
• A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug
• Deciphering the potential pathogeny of rare tracheal adenoid cystic carcinoma by single‑cell RNA‑sequencing
• Adenoid cystic carcinoma (ACC)
• Completed Studies – Adenoid Cystic Carcinoma Research Foundation